Consequences of intermittent calcitriol therapy in pediatric patients with secondary hyperparathyroidism.
Salusky
I B
IB
The Department of Pediatrics, UCLA School of Medicine, Los Angeles, California, USA.
Goodman
W G
WG
Kuizon
B D
BD
D000284:Administration, Oral; D000293:Adolescent; D001842:Bone and Bones / Q000473:pathology; D002117:Calcitriol / Q000008:administration & dosage*; D002118:Calcium / Q000097:blood; D002648:Child; D004334:Drug Administration Schedule; D006128:Growth; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000097:blood; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D012709:Serum Albumin / Q000032:analysis
D010281:Parathyroid Hormone; D012709:Serum Albumin; D002117:Calcitriol; D002118:Calcium